Breakthrough Treatment Revolutionizes Ankylosing Spondylitis Care: Global Market Set for Major Growth

Global Ankylosing Spondylitis Market: Growth Trends, Advancements, and Challenges: https://www.alliedmarketresearch.com/ankylosing-spondylitis-market-A10266

The global ankylosing spondylitis (AS) market was valued at $5,140.94 million in 2020 and is projected to reach $8,110.59 million by 2030, at a CAGR of 4.6% between 2021 and 2030. Ankylosing spondylitis is a chronic inflammatory disorder that primarily affects the spine, causing vertebrae to fuse over time, which can result in a hunched posture and restricted mobility. While the disease has no known cure, effective management through medication and physical therapy can alleviate symptoms and prevent complications.

𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A10266

Understanding Ankylosing Spondylitis: Symptoms and Risk Factors
AS typically presents as pain and stiffness in the lower back and hips, especially during periods of inactivity or in the mornings. Other symptoms may include neck pain, fatigue, and reduced mobility. While the exact cause of AS remains unknown, genetic factors play a crucial role, particularly in individuals carrying the HLA-B27 gene. However, only a portion of HLA-B27-positive individuals develop AS, indicating the involvement of other contributing factors.

Diagnosis and Treatment: Current Practices and Innovations
Diagnosis of AS often involves physical examinations and imaging tests like X-rays and MRIs. Although AS cannot be cured, symptoms can be effectively managed with treatments including nonsteroidal anti-inflammatory drugs (NSAIDs), TNF inhibitors, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). Notably, monoclonal antibodies such as Taltz (ixekizumab), approved by the U.S. FDA in 2019, are proving beneficial in managing AS-related inflammation and pain.

Market Drivers and Growth Factors
The rising prevalence of AS is a key driver for the growth of the global AS market. For instance, a study published in the Scandinavian Journal of Rheumatology reported a 7.3% prevalence rate of AS in Spain. The growing number of orthopedic hospitals and diagnostic centers, along with advancements in treatment options like monoclonal antibodies, further bolster market expansion. However, high treatment costs and potential side effects from AS therapies may hamper market growth.

Segmentation and Regional Outlook
The ankylosing spondylitis market is segmented by drug class, distribution channel, and region. NSAIDs dominated the market in 2020, but TNF inhibitors are expected to witness substantial growth due to ongoing therapeutic advancements. In terms of distribution, retail pharmacies held the largest market share, attributed to their accessibility for patients. The hospital pharmacy segment is also projected to grow, driven by an increasing number of specialized facilities.

Regionally, North America led the AS market in 2020, owing to a well-established healthcare infrastructure and the presence of key pharmaceutical manufacturers. Asia-Pacific, however, is poised for the highest growth rate (6.1% CAGR), fueled by a growing population, increased hospital infrastructure, and rising awareness of AS treatments.

Challenges and Future Outlook
The global AS market faces challenges such as the high cost of treatments and the potential side effects of long-term drug use. Despite these hurdles, continued research and therapeutic advancements, including the development of more effective biologics and personalized medicine approaches, are likely to drive market growth in the coming years.

Key Players in the Market
Leading companies in the AS market include AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, UCB Inc., and Gilead Sciences. These companies are at the forefront of developing innovative treatments to improve the quality of life for AS patients globally.

𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/A10266

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.